Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dezima Pharma BV

Division of Amgen Inc.
www.dezimapharma.com

Latest From Dezima Pharma BV

BioGeneration Ventures Leads Europe's Seed Investing With New Fund

A new VC fund raised by the Netherlands firm, BioGeneration Ventures, has attracted pharma corporate and private investors and is now one of the largest-ever funds focused on making seed investments in European biotech companies.

Financing StartUps and SMEs

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Sales & Earnings Business Strategies

Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target

Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.

Financing StartUps and SMEs

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

Leadership Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Rob de Ree, CEO
    John Kastelein, PhD, CSO
    Patrick Round, PhD, CMO
  • Contact Info
  • Dezima Pharma BV
    Phone: 35 699 3000
    Gooimeer 2-35
    Nardeen, 1411 DC
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register